Key facts
- It has raised $130.2M across 5 recorded rounds; the latest was Early Stage VC ($13.2M) in Jul 2023.
- Notable investors include F-Prime Capital, Gates Foundation, Logos Capital, Arboretum Ventures, 5AM Ventures — 11 tracked in total.
- RareCyte has filed 5 Form Ds with the SEC since 2017, most recently Jul 2023 ($13.2M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for RareCyte
Funding rounds
5 roundsAbout RareCyte
Developer of precision biology products intended to detect circulating tumor cells. The company designs, manufactures, and markets worldwide end-to-end integrated platforms that provide advances in discovery, translational, and future clinical markets, enabling medical researchers to monitor circulating tumor cell counts and biomarker expression over time for clinical research.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2009
- Employees
- 64
- Website
- rarecyte.com/
- Ownership
- Privately Held (backing)
RareCyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RareCyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RareCyte in its N-PORT filings yet. We sweep new filings monthly.